2025年诺贝尔生理学或医学奖揭晓，这些国内药企已布局相关领域

Group 1 - The Nobel Prize in Physiology or Medicine for 2025 was awarded to scientists Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their contributions to peripheral immune tolerance research, specifically the discovery of regulatory T cells [1][3] - The prize amount is 11 million Swedish Krona, approximately 8.32 million RMB, which will be equally divided among the three winners [1] - Their discoveries are expected to lead to new directions in the treatment of autoimmune diseases and the improvement of cancer immunotherapy [1][5] Group 2 - Domestic companies are actively engaging in the field of regulatory T cell therapy, with collaborations and clinical projects underway [5][6] - On May 29, 2025, Haier International Cell Bank and Cellxin Biotech initiated a clinical application project focused on regulatory T cell therapy for conditions like Amyotrophic Lateral Sclerosis (ALS) [5] - Cellxin Biotech announced that its clinical research project on the safety and tolerability of regulatory T cell therapy for neurodegenerative diseases received ethical approval from Zhengzhou University First Affiliated Hospital [5] - He Yuan Biological signed a strategic cooperation agreement with Cellxin Biotech to provide clinical trial sample preparation and testing services for Treg cell therapy [5] - Binoji Biotech, established in November 2021, focuses on innovative T cell therapies for solid tumors and autoimmune diseases, with its product BEN-301 aimed at treating autoimmune diseases currently in preclinical development [6]